Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study

This observational study follows patients with advanced bile duct cancer (cholangiocarcinoma) who have a specific genetic mutation called IDH1 R132 and are being treated with ivosidenib, a targeted therapy approved for this mutation. The study collects real-world data on how well the treatment works and how patients experience it. **You may be eligible if...** - You are 18 years or older - You have locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a confirmed IDH1 R132 mutation - You have received at least one prior systemic treatment - Your doctor has decided to treat you with ivosidenib per standard prescribing guidelines - You have given written informed consent within 6 weeks of your first ivosidenib dose **You may NOT be eligible if...** - You do not have an IDH1 R132 mutation - You have not had prior therapy - You do not meet the prescribing guidelines for ivosidenib Talk to your doctor to see if this trial is right for you.